Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) EBITDA: 2017-2024

Historic EBITDA for DiaMedica Therapeutics (DMAC) over the last 8 years, with Dec 2024 value amounting to -$24.4 million.

  • DiaMedica Therapeutics' EBITDA fell 26.61% to -$2.5 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$10.6 million, marking a year-over-year decrease of 85.68%. This contributed to the annual value of -$24.4 million for FY2024, which is 26.56% down from last year.
  • According to the latest figures from FY2024, DiaMedica Therapeutics' EBITDA is -$24.4 million, which was down 26.56% from -$19.3 million recorded in FY2023.
  • DiaMedica Therapeutics' 5-year EBITDA high stood at -$12.3 million for FY2020, and its period low was -$24.4 million during FY2024.
  • Over the past 3 years, DiaMedica Therapeutics' median EBITDA value was -$19.3 million (recorded in 2023), while the average stood at -$19.1 million.
  • Data for DiaMedica Therapeutics' EBITDA shows a maximum YoY crashed of 40.89% (in 2023) over the last 5 years.
  • Over the past 5 years, DiaMedica Therapeutics' EBITDA (Yearly) stood at -$12.3 million in 2020, then fell by 10.94% to -$13.6 million in 2021, then decreased by 0.43% to -$13.7 million in 2022, then crashed by 40.89% to -$19.3 million in 2023, then dropped by 26.56% to -$24.4 million in 2024.